Article
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Oncology reports - 1 Jul 2016
Jiang Ze-Bo, Huang Jun, Xie Chun, Li Xia, Liu Liping, He Jiaxi, Pan Hui, Huang Liyan, Fan Xing-Xing, Yao Xiao-Jun, Xie Ying, Li Na, Liu Liang, He Jian-Xing, Leung Elaine Lai-Han
Abstract excerpt
EGFR and KRAS mutations are the two most common driver mutations in non-small cell lung cancer (NSCLC). Molecular target-based therapy using small molecules such as gefitinib has been used for inhibiting EGFR with good initial responses; however, drug resistance is common when using a mono-targeting strategy. At present, KRAS remains an undruggable target. As such, the development of new drugs targeting the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.